In order to reduce the burden of multiple testing, we limited further analyses to those trajectories containing the most frequent ccRCC driver events: VHL, PBRM1, SETD2, BAP1, PI3K/AKT/mTOR pathway mutations, or driver SCNAs (Figure 1B). This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.